Gangneung, South Korea

BongGeun Song

This inventor holds 1 USPTO granted patent. Top assignee: Korea Institute of Science and Technology. Active years: 2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: BongGeun Song. Retrieved from https://idiyas.com/inventor/bonggeun-song

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 12.0

ph-index = 1


Company Filing History:


Years Active: 2021

Loading Chart...
1 patent (USPTO):Explore Patents

Title: BongGeun Song: Innovator in Nephrotoxicity Prevention

Introduction

BongGeun Song is a notable inventor based in Gangneung-si, South Korea. He has made significant contributions to the field of nephrotoxicity prevention through his innovative research and development.

Latest Patents

BongGeun Song holds 1 patent for his invention titled "Composition for preventing or reducing nephrotoxicity and use thereof." This composition includes an extract or an active component aimed at preventing or reducing nephrotoxicity, showcasing his commitment to advancing medical science.

Career Highlights

He is currently affiliated with the Korea Institute of Science and Technology, where he continues to engage in groundbreaking research. His work is pivotal in addressing critical health issues related to nephrotoxicity.

Collaborations

BongGeun Song collaborates with esteemed colleagues such as Jungyeob Ham and Young Tae Park, contributing to a dynamic research environment that fosters innovation.

Conclusion

BongGeun Song's contributions to nephrotoxicity prevention highlight his role as a leading inventor in the field. His dedication to research and collaboration continues to pave the way for advancements in medical science.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…